TY - JOUR
T1 - Clinical characteristics and outcome of human herpesvirus-6 encephalitis after allogeneic hematopoietic stem cell transplantation
AU - Ogata, M.
AU - Oshima, K.
AU - Ikebe, T.
AU - Takano, K.
AU - Kanamori, H.
AU - Kondo, T.
AU - Ueda, Y.
AU - Mori, T.
AU - Hashimoto, H.
AU - Ogawa, H.
AU - Eto, T.
AU - Ueki, T.
AU - Miyamoto, T.
AU - Ichinohe, T.
AU - Atsuta, Y.
N1 - Funding Information:
We express our appreciation for the work of all of the physicians and data managers who contributed valuable data to the JSHCT and JDCHCT. We also thank members of the Transplant Registry Unified Management committees for their data management. This work was supported in part by the Practical Research Project for Allergic Diseases and Immunology from the Japan Agency for Medical Research and Development, AMED (to YA) and Research Program on Practical Research for Innovative Cancer Control from AMED (to TF).
Publisher Copyright:
© 2017 Macmillan Publishers Limited, part of Springer Nature.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - In this retrospective analysis using the Transplant Registry Unified Management Program, we identified 145 patients with human herpesvirus (HHV)-6 encephalitis among 6593 recipients. The cumulative incidences of HHV-6 encephalitis at 100 days after transplantation in all patients, recipients of bone marrow or PBSCs and recipients of cord blood were 2.3%, 1.6% and 5.0%, respectively. Risk factors identified in multivariate analysis were male sex, type of transplanted cells (relative risk in cord blood transplantation, 11.09, Po0.001; relative risk in transplantation from HLA-mismatched unrelated donor, 9.48, Po0.001; vs transplantation from HLA-matched related donor) and GvHD prophylaxis by calcineurin inhibitor alone. At 100 days after transplantation, the overall survival rate was 58.3% and 80.5% among patients with and without HHV-6 encephalitis, respectively (Po0.001). Neuropsychological sequelae remained in 57% of 121 evaluated patients. With both foscarnet and ganciclovir, full-dose therapy (foscarnet ?180 mg/kg, ganciclovir ?10 mg/kg) was associated with better response rate (foscarnet, 93% vs 74%, P = 0.044; ganciclovir, 84% vs 58%, P = 0.047). HHV-6 encephalitis is not rare not only in cord blood transplant recipients but also in recipients of HLA-mismatched unrelated donors. In this study, development of HHV-6 encephalitis was associated with a poor survival rate, and neurological sequelae remained in many patients.
AB - In this retrospective analysis using the Transplant Registry Unified Management Program, we identified 145 patients with human herpesvirus (HHV)-6 encephalitis among 6593 recipients. The cumulative incidences of HHV-6 encephalitis at 100 days after transplantation in all patients, recipients of bone marrow or PBSCs and recipients of cord blood were 2.3%, 1.6% and 5.0%, respectively. Risk factors identified in multivariate analysis were male sex, type of transplanted cells (relative risk in cord blood transplantation, 11.09, Po0.001; relative risk in transplantation from HLA-mismatched unrelated donor, 9.48, Po0.001; vs transplantation from HLA-matched related donor) and GvHD prophylaxis by calcineurin inhibitor alone. At 100 days after transplantation, the overall survival rate was 58.3% and 80.5% among patients with and without HHV-6 encephalitis, respectively (Po0.001). Neuropsychological sequelae remained in 57% of 121 evaluated patients. With both foscarnet and ganciclovir, full-dose therapy (foscarnet ?180 mg/kg, ganciclovir ?10 mg/kg) was associated with better response rate (foscarnet, 93% vs 74%, P = 0.044; ganciclovir, 84% vs 58%, P = 0.047). HHV-6 encephalitis is not rare not only in cord blood transplant recipients but also in recipients of HLA-mismatched unrelated donors. In this study, development of HHV-6 encephalitis was associated with a poor survival rate, and neurological sequelae remained in many patients.
UR - http://www.scopus.com/inward/record.url?scp=85032626825&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032626825&partnerID=8YFLogxK
U2 - 10.1038/bmt.2017.175
DO - 10.1038/bmt.2017.175
M3 - Article
C2 - 28783148
AN - SCOPUS:85032626825
SN - 0268-3369
VL - 52
SP - 1563
EP - 1570
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 11
ER -